RXRX

Recursion Pharmaceuticals Inc

Feb 20 • 02:36PM ET

3.40

-0.32 -8.47 %

Healthcare • Biotechnology • USA • NASD

Peers: ABCL SDGR DNLI NBIX CRSP BEAM NTLA EDIT VRTX RGNX

| Held by: ARKK VTI XBI ARKG VB IWM VBK VXF IWO IBB

Index	RUT	P/E	-	EPS (ttm)	-1.81	Insider Own	16.46%	Shs Outstand	485.21M	Perf Week	-4.89%
Market Cap	1.77B	Forward P/E	-	EPS next Y	-1.14	Insider Trans	-1.88%	Shs Float	434.79M	Perf Month	-26.14%
Enterprise Value	1.19B	PEG	-	EPS next Q	-0.30	Inst Own	56.56%	Short Float	38.08%	Perf Quarter	-18.15%
Income	-715.54M	P/S	40.56	EPS this Y	7.30%	Inst Trans	3.61%	Short Ratio	7.43	Perf Half Y	-28.62%
Sales	43.69M	P/B	1.60	EPS next Y	27.38%	ROA	-67.31%	Short Interest	165.55M	Perf YTD	-16.75%
Book/sh	2.13	P/C	2.67	EPS next 5Y	17.77%	ROE	-91.06%	52W High	10.87 -68.68%	Perf Year	-67.10%
Cash/sh	1.27	P/FCF	-	EPS past 3/5Y	-15.58% -35.28%	ROIC	-64.53%	52W Low	2.98 14.26%	Perf 3Y	-57.38%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	79.47% 90.93%	Gross Margin	-160.40%	Volatility	9.56% 7.45%	Perf 5Y	-
Dividend TTM	-	EV/Sales	27.27	EPS Y/Y TTM	-18.46%	Oper. Margin	-1656.17%	ATR (14)	0.29	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.60	Sales Y/Y TTM	-32.98%	Profit Margin	-1637.81%	RSI (14)	35.48	Recom	2.25
Dividend Gr. 3/5Y	- -	Current Ratio	4.60	EPS Q/Q	-7.02%	SMA20	-14.17%	Beta	0.96	Target Price	7.00
Payout	-	Debt/Eq	0.08	Sales Q/Q	-80.16%	SMA50	-20.55%	Rel Volume	0.78	Prev Close	3.72
Employees	-	LT Debt/Eq	0.06	Earnings	Feb 25 BMO	SMA200	-30.24%	Avg Volume	22.30M	Price	3.40
IPO	Apr 16, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	4.53% -70.60%	Trades		Volume	13,918,301	Change	-8.47%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-17-25	Upgrade	JP Morgan	Neutral → Overweight	$11
Jul-03-25	Resumed	Morgan Stanley	Equal-Weight	$5
May-22-23	Initiated	Morgan Stanley	Equal-Weight	$8
Mar-16-23	Initiated	Needham	Buy	$17
Sep-16-22	Initiated	KeyBanc Capital Markets	Overweight	$20
Apr-18-22	Downgrade	BofA Securities	Buy → Neutral	$10
Mar-04-22	Downgrade	SVB Leerink	Outperform → Mkt Perform	$10
Sep-21-21	Initiated	Berenberg	Buy	$37
May-11-21	Initiated	SVB Leerink	Outperform	$33
May-11-21	Initiated	KeyBanc Capital Markets	Overweight	$36
May-11-21	Initiated	JP Morgan	Neutral	$32
May-11-21	Initiated	Goldman	Neutral	$34
May-11-21	Initiated	BofA Securities	Buy	$31

Show Previous Ratings

Today 10:01AM	Cathie Wood Pours $24 Million to This AI Software Stock (GuruFocus.com) -8.47%
Feb-19-26 05:10PM	Travere Therapeutics (TVTX) Matches Q4 Earnings Estimates (Zacks) +5.38%
04:47PM	Nvidia Dumped Recursion Pharmaceuticals Stock. Should You? (Barchart)
05:27AM	Nvidia Dumped It, Cathie Wood Snapped It Up. This Pharma Stock Is Splitting Wall Street. (Barrons.com)
11:14AM	NVIDIAs 13F Bombshell: A New AI Power Trio Emerges (MarketBeat)
05:50PM	Loading…
Feb-18-26 05:50PM	Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider (Zacks)
04:40PM	Applied Digital, WeRide Stocks Drop. Blame Nvidia. (Barrons.com)
02:07PM	Recursion Pharmaceuticals Stock Drops: What's Behind It? (Benzinga)
01:21PM	Nvidia Sold Its Stakes in These Firms. The Stocks Are Sliding. (Investopedia)
09:37AM	Applied Digital, WeRide Stocks Drop After Nvidia Sells Holdings (The Wall Street Journal)
08:30AM	Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25 (GlobeNewswire)
05:43AM	Applied Digital, Recursion Pharmaceuticals Stocks Drop. Blame Nvidia. (Barrons.com)
Feb-17-26 04:58PM	Cathie Wood Buys COIN, HOOD (GuruFocus.com)
09:48AM	Recursion Pharmaceuticals to Report Q4 Earnings: What's in the Cards? (Zacks)
Feb-12-26 10:00AM	2 Biotech Stocks to Buy as AI Drug Discovery Lifts Off (24/7 Wall St.)
07:59AM	Loading…
07:59AM	Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules (GlobeNewswire)
Feb-10-26 05:45PM	Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know (Zacks)
Feb-04-26 05:50PM	Recursion Pharmaceuticals (RXRX) Suffers a Larger Drop Than the General Market: Key Insights (Zacks) -8.72%
Jan-29-26 05:50PM	Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors (Zacks)
09:25AM	AI-Native Data Core Triggers Multi-Trillion Dollar Healthcare Structural Shift (PR Newswire)
06:15AM	Forget 2025: These 2 Growth Stocks Could Soar in 2026 (Motley Fool)
Jan-28-26 09:21PM	Can This Beaten-Down AI Stock Bounce Back in 2026? (Motley Fool)
Jan-24-26 03:35AM	Is Recursion Pharmaceuticals Inc. (RXRX) The Best Overlooked Penny Stock to Invest In? (Insider Monkey)
Jan-23-26 05:50PM	Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors (Zacks)
Jan-20-26 10:14AM	Recursion Pharmaceuticals, Inc. (RXRX): A Bull Case Theory (Insider Monkey) -5.78%
Jan-18-26 12:30PM	JPMorgan Upgrades Recursion Pharmaceuticals, Inc. (RXRX) on FAP Treatment Prospects (Insider Monkey)
Jan-16-26 05:05PM	2 AI Stocks to Buy in 2026, and 1 to Avoid (Motley Fool) -5.78%
Jan-15-26 05:50PM	Recursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to Note (Zacks)
Jan-08-26 05:50PM	Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: What You Should Know (Zacks)
Jan-07-26 08:20PM	Recursion Pharmaceuticals (RXRX) Climbs 6.8% Ahead of Next Week's Business Updates (Insider Monkey) +6.81%
07:59AM	Loading…
Jan-06-26 07:59AM	Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-02-26 03:22PM	Getty Images, Torm, and More Stocks See Action From Activist Investors (Barrons.com)
09:10AM	JPMorgan Boosts Rating on Recursion Pharmaceuticals (RXRX) Amid AI-Driven Drug Pipeline (Insider Monkey)
Jan-01-26 07:45AM	Forget Recursion Pharmaceuticals Stock. This Is a Much Better Buy. (Motley Fool)
Dec-30-25 11:49PM	Cathie Wood's ARK Investment Buys 755K Shares Of Recursion Pharmaceuticals, Inc. (RXRX) (Insider Monkey)
Dec-29-25 11:42AM	Recursion Pharmaceuticals Reports Positive Phase 1b/2 TUPELO Trial Results, Validating AI-Driven Therapy for FAP (Insider Monkey)
08:55AM	Want Better Returns? Don't Ignore These 2 Medical Stocks Set to Beat Earnings (Zacks)
Dec-28-25 12:46PM	Recursion Pharmaceuticals Rises as Positive Phase 1b/2 Trial Results for REC-4881 Validate AI-Driven Drug Discovery Platform (Insider Monkey)
Dec-24-25 09:00AM	Cathie Wood Is Doubling Down on Recursion Pharmaceuticals Stock. Should You Buy RXRX Here? (Barchart)
Dec-21-25 07:40AM	Is Recursion Pharmaceuticals, Inc. (RXRX) the Best Fundamentally Strong Penny Stock to Buy? (Insider Monkey)
Dec-19-25 07:33AM	Cathie Wood Keeps Dumping Tesla Stock -- Here is Why (GuruFocus.com)
Dec-18-25 05:24AM	Why Recursion Pharmaceuticals, Inc. (RXRX)'s Upside Case Hasn't Fully Convinced Yet (Insider Monkey) -5.13%
Dec-17-25 05:27PM	Why Recursion Pharmaceuticals Stock Vaulted 11% Higher on Wednesday (Motley Fool) +11.43%
Dec-11-25 10:17AM	Platform Technologies Drive $211B Surge in Precision Cancer Treatment (PR Newswire)
Dec-08-25 05:30PM	Why Recursion Pharamaceuticals Topped the Market Today (Motley Fool)
07:30AM	Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks (GlobeNewswire)
12:32AM	Jim Cramer on Recursion: "It Is so Low That It Comes in Under the Category of Speculative" (Insider Monkey)
Dec-05-25 11:30AM	Recursion Pharmaceuticals (RXRX) Up 6.5% Since Last Earnings Report: Can It Continue? (Zacks)
Dec-04-25 09:04PM	Lightning Round: Recursion Pharmaceuticals and NuScale Power (CNBC TV) +5.58%
06:05AM	10 AI Stocks Worth Buying Right Now (Motley Fool)
Dec-01-25 08:30AM	Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025 (GlobeNewswire) -5.83%
Nov-28-25 06:45AM	Cathie Wood Dumps Millions in Tesla -- Loads Up on Coinbase After Sharp Swings (GuruFocus.com)
Nov-24-25 08:53AM	Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock? (Motley Fool)
Nov-22-25 10:11AM	Recursion (RXRX) Jumps 8% on Bargain-Hunting (Insider Monkey)
Nov-21-25 05:02AM	Is Recursion Pharmaceuticals Inc. (RXRX) One of the Best Mid Cap Stocks to Buy According to Hedge Funds? (Insider Monkey) +8.31%
Nov-19-25 08:13AM	Is Recursion Pharmaceuticals a Meme Stock? (Motley Fool)
Nov-12-25 09:45AM	Forget Recursion Pharmaceuticals: This Could Be an Even Better Artificial Intelligence (AI) Stock (Motley Fool)
Nov-06-25 09:24AM	RXRX Q3 Loss Narrower Than Expected, Revenues Decline Y/Y (Zacks) -6.85%
Nov-05-25 07:40AM	Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
06:34AM	Recursion Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
06:30AM	Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
06:28AM	Recursion Announces CEO Transition Plan to Drive Next Phase of Growth (GlobeNewswire)
Nov-04-25 08:45AM	3 Things Investors Need to Know About Recursion Pharmaceuticals (Motley Fool) -8.09%
08:00AM	Recursion to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-03-25 11:19AM	Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards? (Zacks)
Oct-31-25 06:15AM	Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock? (Motley Fool)
Oct-29-25 10:00AM	Earnings Preview: Recursion Pharmaceuticals (RXRX) Q3 Earnings Expected to Decline (Zacks)
Oct-28-25 05:50PM	Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors (Zacks) -6.19%
08:00AM	Recursion to Report Third Quarter 2025 Business Updates and Financial Results on November 5th (GlobeNewswire)
Oct-22-25 05:50PM	Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know (Zacks) -5.89%
08:56AM	Jim Cramer on Recursion Pharmaceuticals: "Now, It's a Meme Stock" (Insider Monkey)
Oct-21-25 12:56PM	Recursion Pharmaceuticals (RXRX) Surges 14% Ahead of Earnings (Insider Monkey) -8.53%
10:00AM	Up 25% in 1 Month, Is This Stock a Buy? (Motley Fool)
Oct-19-25 04:00AM	3 Growth Stocks to Invest $1,000 in Right Now (Motley Fool)
Oct-16-25 05:50PM	Recursion Pharmaceuticals (RXRX) Suffers a Larger Drop Than the General Market: Key Insights (Zacks) -6.33% -7.86%
10:30AM	Recursion Pharmaceuticals (RXRX) Extends Gains, Jumps 15.28% on Major AI Event (Insider Monkey)
09:31AM	Is Recursion Pharmaceuticals a Millionaire Maker? (Motley Fool)
Oct-13-25 12:12PM	2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk (MarketBeat)
Oct-12-25 09:45AM	4 Healthcare Stocks to Buy Now (Motley Fool)
Oct-09-25 05:00AM	Recursion Pharmaceuticals (RXRX) Climbs 16% Ahead of AI Conference (Insider Monkey)
Oct-08-25 11:22AM	Recursion Pharmaceuticals, Inc. (RXRX): A Bull Case Theory (Insider Monkey) +16.44%
10:22AM	Stock Market Today: Stocks Tick Up Ahead of FOMC Minutes Release (TheStreet)
Oct-07-25 05:50PM	Recursion Pharmaceuticals (RXRX) Dips More Than Broader Market: What You Should Know (Zacks) -5.42%
Oct-03-25 09:51AM	Recursion Pharmaceuticals (RXRX) Surges 8.2%: Is This an Indication of Further Gains? (Zacks)
Sep-30-25 02:49PM	Needham Reiterates a Buy on Recursion Pharmaceuticals (RXRX) (Insider Monkey)
Sep-29-25 09:02AM	Nvidia Has Invested in These 6 Companies. Should You Follow Suit? (Motley Fool)
01:22AM	Jim Cramer on Recursion: "I Need to See a Proof of Concept Here" (Insider Monkey)
Sep-28-25 10:00AM	Where Will Recursion Pharmaceuticals Be in 5 Years? (Motley Fool)
09:32AM	The Biotech Stock That's Too Risky for Most Investors (Motley Fool)
07:00AM	Nvidias $100 billion OpenAI investment raises eyebrows and a key question: How much of the AI boom is just Nvidias cash being recycled? (Fortune)
Sep-27-25 06:45AM	10 Hidden-Gem AI Stocks to Buy Right Now (Motley Fool)
Sep-26-25 04:42AM	Prediction: 2 Stocks That Will Be Worth More Than BigBear.ai 5 Years From Now (Motley Fool)
Sep-25-25 09:15AM	Looking for the Next Big Pop? Heres Why Recursion Pharmaceuticals (RXRX) Could Do a Dead-Cat Bounce (Barchart) -5.12%
Sep-22-25 05:50PM	Recursion Pharmaceuticals (RXRX) Laps the Stock Market: Here's Why (Zacks)
Sep-21-25 09:26AM	Recursion Pharmaceuticals, Inc. (RXRX) Secures $12.5M Milestone From Rallybio as REV102 Advances (Insider Monkey)
Sep-15-25 05:50PM	Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: What You Should Know (Zacks)
08:17AM	Needham Retains Buy Rating on Recursion Pharmaceuticals, Maintains PT at $8 (Insider Monkey)
04:44AM	Nvidia Has $4.3 Billion Invested in These 6 Artificial Intelligence (AI) Stocks. Here's the Best of the Bunch. (Motley Fool)
Sep-03-25 06:00AM	When You Buy Nvidia Stock, You Get a Bonus: An Artificial Intelligence (AI) ETF of Sorts (Motley Fool)
Sep-02-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 4, 2013 and is headquartered in Salt Lake City, UT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gibson Christopher	Director	Feb 19 '26	Sale	3.46	40,000	138,400	906,556	Feb 19 07:30 PM
Taylor Ben R	Chief Financial Officer	Feb 18 '26	Sale	3.08	13,426	41,352	1,195,349	Feb 19 07:30 PM
Gibson Christopher	Director	Feb 19 '26	Proposed Sale	3.46	40,000	138,400		Feb 19 10:27 AM
Taylor Ben R	Officer	Feb 18 '26	Proposed Sale	3.08	13,426	41,352		Feb 18 12:21 PM
Gibson Christopher	Director	Feb 04 '26	Sale	4.12	40,000	164,800	913,839	Feb 06 05:53 PM
Borgeson Blake	Director	Feb 03 '26	Sale	4.20	220,000	924,000	6,429,863	Feb 06 05:53 PM
Gibson Christopher	Director	Feb 04 '26	Proposed Sale	4.12	40,000	164,800		Feb 04 09:50 AM
Borgeson Blake	Director	Feb 03 '26	Proposed Sale	4.20	220,000	924,000		Feb 03 11:26 AM
Gibson Christopher	Director	Jan 20 '26	Sale	4.47	40,000	178,800	913,839	Jan 22 07:34 PM
Gibson Christopher	Director	Jan 20 '26	Proposed Sale	4.47	40,000	178,800		Jan 20 11:26 AM
Borgeson Blake	Director	Jan 06 '26	Sale	4.36	220,000	959,200	6,649,863	Jan 08 05:01 PM
Gibson Christopher	Director	Jan 05 '26	Sale	4.25	40,000	170,000	933,839	Jan 07 05:04 PM
Borgeson Blake	Director	Jan 06 '26	Proposed Sale	4.36	220,000	959,200		Jan 06 09:40 AM
Gibson Christopher	Director	Jan 05 '26	Proposed Sale	4.25	40,000	170,000		Jan 05 11:07 AM
Taylor Ben R	Chief Financial Officer	Dec 29 '25	Sale	4.18	21,383	89,381	761,550	Dec 30 07:35 PM
Khan Najat	Chief R&D Commercial Officer	Dec 22 '25	Sale	4.41	124,403	548,592	611,135	Dec 29 05:24 PM
Taylor Ben R	Officer	Dec 29 '25	Proposed Sale	4.18	21,383	89,381		Dec 29 09:41 AM
Najat Khan	Officer	Dec 22 '25	Proposed Sale	4.41	124,403	548,588		Dec 22 12:20 PM
Gibson Christopher	Chief Executive Officer	Dec 19 '25	Sale	4.50	40,000	180,000	913,839	Dec 19 05:04 PM
Gibson Christopher	Officer	Dec 19 '25	Proposed Sale	4.50	40,000	180,000		Dec 19 09:52 AM
Gibson Christopher	Chief Executive Officer	Dec 04 '25	Sale	4.63	40,000	185,200	933,839	Dec 05 07:20 PM
Borgeson Blake	Director	Dec 02 '25	Sale	4.37	220,000	961,400	6,869,863	Dec 04 04:51 PM
Gibson Christopher	Officer	Dec 04 '25	Proposed Sale	4.63	40,000	185,200		Dec 04 10:01 AM
Borgeson Blake	Director	Dec 02 '25	Proposed Sale	4.37	220,000	961,400		Dec 02 12:15 PM
Gibson Christopher	Chief Executive Officer	Nov 19 '25	Sale	4.16	40,000	166,400	913,839	Nov 19 07:37 PM
Gibson Christopher	Officer	Nov 19 '25	Proposed Sale	4.16	40,000	166,400		Nov 19 10:17 AM
Gibson Christopher	Chief Executive Officer	Nov 04 '25	Sale	5.21	40,000	208,400	974,229	Nov 06 04:23 PM
Gibson Christopher	Officer	Nov 04 '25	Proposed Sale	5.21	40,000	208,400		Nov 04 09:51 AM
Gibson Christopher	Chief Executive Officer	Oct 23 '25	Sale	5.70	100,000	570,000	954,229	Oct 24 06:49 PM
Gibson Christopher	Officer	Oct 23 '25	Proposed Sale	5.70	100,000	570,000		Oct 23 10:37 AM
Gibson Christopher	Chief Executive Officer	Oct 10 '25	Sale	6.04	100,000	604,000	974,229	Oct 10 06:03 PM
Gibson Christopher	Officer	Oct 10 '25	Proposed Sale	6.04	100,000	604,000		Oct 10 10:24 AM
Gibson Christopher	Chief Executive Officer	Sep 25 '25	Sale	4.76	100,000	476,000	954,229	Sep 26 06:32 PM
Gibson Christopher	Officer	Sep 25 '25	Proposed Sale	4.76	100,000	476,000		Sep 25 09:49 AM
Gibson Christopher	Chief Executive Officer	Sep 10 '25	Sale	4.71	100,000	471,000	974,229	Sep 12 04:24 PM
Gibson Christopher	Officer	Sep 10 '25	Proposed Sale	4.71	100,000	471,000		Sep 10 11:10 AM
Gibson Christopher	Chief Executive Officer	Aug 26 '25	Sale	4.84	100,000	484,000	954,229	Aug 28 08:00 PM
Gibson Christopher	Officer	Aug 26 '25	Proposed Sale	4.84	100,000	484,000		Aug 26 10:03 AM
Khan Najat	Chief R&D Commercial Officer	Aug 18 '25	Sale	5.52	36,599	202,173	668,197	Aug 19 06:22 PM
Khan Najat	Officer	Aug 18 '25	Proposed Sale	5.52	36,599	202,169		Aug 18 03:18 PM
Gibson Christopher	Chief Executive Officer	Aug 11 '25	Sale	5.28	500,300	2,641,584	1,004,619	Aug 13 09:03 PM
Gibson Christopher	Chief Executive Officer	Aug 11 '25	Sale	5.28	117,875	622,380	0	Aug 13 09:03 PM
Gibson Christopher	Officer	Aug 11 '25	Proposed Sale	5.28	617,875	3,262,380		Aug 11 03:31 PM
Gibson Christopher	Chief Executive Officer	Mar 27 '25	Sale	6.04	138,574	836,987	1,117,450	Mar 28 04:52 PM
Gibson Christopher	Officer	Mar 27 '25	Proposed Sale	6.04	138,574	836,987		Mar 27 12:02 PM
Gibson Christopher	Chief Executive Officer	Mar 05 '25	Sale	6.58	20,000	131,600	1,256,024	Mar 07 04:16 PM
Gibson Christopher	Chief Executive Officer	Mar 06 '25	Sale	6.37	20,000	127,400	1,256,024	Mar 07 04:16 PM
Gibson Christopher	Officer	Mar 06 '25	Proposed Sale	6.37	20,000	127,400		Mar 06 11:55 AM
Gibson Christopher	Officer	Mar 05 '25	Proposed Sale	6.58	20,000	131,600		Mar 05 10:13 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RXRX

Recursion Pharmaceuticals Inc

Upgrade your FINVIZ experience